Overview

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Cyclosporine
Cyclosporins